Shares of the gene therapy developer rose 12.5% to $9.55 in premarket trading on Monday after the news. Sign up here. Under the deal, MeiraGTx will get an upfront payment of $75 million and ...

MeiraGTx (MGTX) shares added ~18% in the premarket on Monday after the genetic medicines company announced a broad strategic collaboration with Eli Lilly (LLY) to develop and commercialize gene ...

Investing.com -- MeiraGTx Holdings (NASDAQ:MGTX) stock surged 11% after announcing a strategic collaboration with Eli Lilly (NYSE:LLY) focused on gene therapies for eye diseases. The partnership ...

MeiraGTx is cashing in on a gene therapy that restored vision to 11 children who were born legally blind, licensing the program to Eli Lilly in a deal potentially worth more than $475 million. The ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. MeiraGTx has formed another partnership with a large ...

(Reuters) -MeiraGTx Holdings has signed a deal with Eli Lilly, potentially worth over $475 million, granting the pharma giant rights to its experimental gene ‌therapy for a rare, inherited disorder ...

Eli Lilly is dominating the large and rapidly growing incretin analog market in the U.S. with its GLP-1 drug, tirzepatide. Its investigational oral GLP-1 drug, orforglipron, could significantly expand ...

Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma companies deciding to steer clear of the cell and gene therapy sector. Eli Lilly ...

Oct 24 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Friday it would acquire gene therapy developer Adverum Biotechnologies (ADVM.O), opens new tab in a deal valued at up to $261.7 million, ...

Eli Lilly & Co. agreed to buy Adverum Biotechnologies Inc., a company working to treat blindness, in a deal that ultimately could be worth $261.7 million as it continues a push into gene therapies.

Just as Adverum Biotechnologies' cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy. The prize for Lilly is ixo-vec, an ...